181 related articles for article (PubMed ID: 22920637)
21. Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma.
Kishi S; Obata F; Miki H; Matsuura M; Nishimura K; Tamaki M; Kishi F; Murakami T; Abe H; Nagai K; Abe M; Doi T
Intern Med; 2018 Dec; 57(24):3597-3602. PubMed ID: 30101939
[TBL] [Abstract][Full Text] [Related]
22. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
23. Myeloma kidney: improving clinical outcomes?
Haynes R; Leung N; Kyle R; Winearls CG
Adv Chronic Kidney Dis; 2012 Sep; 19(5):342-51. PubMed ID: 22920645
[TBL] [Abstract][Full Text] [Related]
24. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
Hutchison CA; Cockwell P; Stringer S; Bradwell A; Cook M; Gertz MA; Dispenzieri A; Winters JL; Kumar S; Rajkumar SV; Kyle RA; Leung N
J Am Soc Nephrol; 2011 Jun; 22(6):1129-36. PubMed ID: 21511832
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition.
Sanders PW; Herrera GA; Kirk KA; Old CW; Galla JH
Lab Invest; 1991 Apr; 64(4):527-37. PubMed ID: 1901926
[TBL] [Abstract][Full Text] [Related]
26. Acute renal failure with lambda light chain-derived crystals in a patient with IgD myeloma.
Toly-Ndour C; Peltier J; Piedagnel R; Coppo P; Sachon E; Ronco P; Rondeau E; Callard P; Aucouturier P
Nephrol Dial Transplant; 2011 Sep; 26(9):3057-9. PubMed ID: 21737515
[TBL] [Abstract][Full Text] [Related]
27. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
Bridoux F; Fermand JP
Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
[TBL] [Abstract][Full Text] [Related]
28. Combined crystalline podocytopathy and tubulopathy associated with multiple myeloma.
Akilesh S; Alem A; Nicosia RF
Hum Pathol; 2014 Apr; 45(4):875-9. PubMed ID: 24439928
[TBL] [Abstract][Full Text] [Related]
29. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
31. Myeloma light chain cast nephropathy, a review.
Sathick IJ; Drosou ME; Leung N
J Nephrol; 2019 Apr; 32(2):189-198. PubMed ID: 29730782
[TBL] [Abstract][Full Text] [Related]
32. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.
Harding S; Provot F; Beuscart JB; Cook M; Bradwell AR; Stringer S; White D; Cockwell P; Hutchison CA
Nephrol Dial Transplant; 2011 Apr; 26(4):1438. PubMed ID: 21406545
[TBL] [Abstract][Full Text] [Related]
33. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.
Basnayake K; Cheung CK; Sheaff M; Fuggle W; Kamel D; Nakoinz S; Hutchison CA; Cook M; Stoves J; Bradwell AR; Cockwell P
J Clin Pathol; 2010 Oct; 63(10):884-7. PubMed ID: 20876319
[TBL] [Abstract][Full Text] [Related]
34. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells.
Li M; Balamuthusamy S; Simon EE; Batuman V
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F82-90. PubMed ID: 18448595
[TBL] [Abstract][Full Text] [Related]
35. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
36. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
38. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
[TBL] [Abstract][Full Text] [Related]
39. Myeloma-related kidney disease.
Leung N; Nasr SH
Adv Chronic Kidney Dis; 2014 Jan; 21(1):36-47. PubMed ID: 24359985
[TBL] [Abstract][Full Text] [Related]
40. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model.
Ying WZ; Allen CE; Curtis LM; Aaron KJ; Sanders PW
J Clin Invest; 2012 May; 122(5):1777-85. PubMed ID: 22484815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
